Task Group Charge
To identify factors contributing to variation in access to and delivery of recommended lung nodule management, staging, and receipt of curative-intent surgery and radiation/SBRT for early-stage NSCLC, access to and use of comphrehensive biomarker testing for targeted therapies, and strategies to overcome the factors contributing to this variation.
Leadership
Gerard A. Silvestri, MD, MS
Task Group Chair
Steering Committee Member
Medical University of South Carolina
Farhood Farjah, MD, MPH
Task Group Vice Chair
University of Washington
Task Group Members
Brett Bade, MD
Yale University
Upal Basu Roy, PhD, MPH
LUNGevity Foundation
Leigh Boehmer, PharmD, BCOP
Association of Community Cancer Centers
Elizabeth David, MD, MAS
University of Southern California
Jordan Garst
ALK Positive Outreach
Louise M. Henderson, PhD, MSPH
University of North Carolina at Chapel Hill
James Jett, MD
National Jewish Health
Bruce Johnson, MD
Dana-Farber Cancer Institute
Edward Kim, MD
Levine Cancer Institute
Jennifer King, PhD
GO2 Foundation for Lung Cancer
Linda Martin, MD, MPH
University of Virginia
Nikki Martin, MA
LUNGevity Foundation
Rhonda Meckstroth
ALK Positive Outreach
Raymond Osarogiagbon, MBBS
Baptist Memorial Healthcare
Shetal Patel, MD, PhD
University of North Carolina at Chapel Hill
Gregory Riely, MD, PhD
Memorial Sloan Kettering Cancer Center
M. Patricia Rivera, MD
University of North Carolina at Chapel Hill
Albert Rizzo, MD
American Lung Association
Liora Sahar, PhD, GISP
American Cancer Society
Helmneh Sineshaw, MD, MPH
American Cancer Society
Robert Suh, MD
University of California, Los Angeles
Douglas Wood, MD
University of Washington
(*) indicates Steering Committee member
Opportunities For Intervention/Influence:
- Address the lack of experience and/or expertise in screen-detected lung nodule management
- Identify strategies to reduce the variation (geographic, SES, income, race/ethnicity, rural, etc.) in access to lung cancer specialists
- Identify strategies to overcome the non-adherence with staging and management guidelines
- Highlight the disparities in receipt of curative-intent surgery for early stage NSCLC and develop strategies to eliminate these disparities
- Develop strategies to reduce the variability in access and use of comprehensive biomarker testing for expression of immune-markers and targeted therapy